FindTrial
Sign In

CPI-006

DRUG2 trials

Sponsors

Corvus Pharmaceuticals, Inc.

Conditions

Bladder CancerCOVID-19Cervical CancerColorectal CancerEndometrial CancerMetastatic Castration Resistant Prostate CancerNon-Small Cell Lung CancerNon-hodgkin Lymphoma

Phase 1

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
CompletedNCT03454451
Corvus Pharmaceuticals, Inc.Bladder Cancer, Cervical Cancer, Colorectal Cancer +10
Start: 2018-04-25End: 2023-02-19Updated: 2023-12-21
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
CompletedNCT04464395
Corvus Pharmaceuticals, Inc.COVID-19
Start: 2020-07-01End: 2021-07-09Updated: 2021-07-21

Related Papers

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Journal for ImmunoTherapy of Cancer2022-12-0122 citations
701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)
Regular and Young Investigator Award Abstracts2021-11-013 citations
325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells
Regular and Young Investigator Award Abstracts2020-11-011 citations
Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.
Journal of Clinical Oncology2019-05-2044 citations
A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
Journal of Clinical Oncology2019-05-208 citations